ASCO GU 2022: KEYNOTE-564 Update Confirms Benefits of Adjuvant Pembrolizumab in Renal Cell Carcinoma
Follow-up is ongoing, as overall survival data remain immature
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.